



GEOVAX TO EXHIBIT AT THE 2009 BIO INTERNATIONAL CONVENTION

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

WHAT: **GeoVax Labs, Inc. (OTC BB: GOVX)**, an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents to share, their strategy for the future and plans to expand preventative trials, currently in Phase 2a, to proof of concept trials in ‘at risk’ humans and move therapeutic trials from non-human primate models to HIV-1 virus infected individuals.

Dr. Harriet Robinson to moderate *“HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a Global Pandemic”*

WHERE: 2009 BIO International Convention
Georgia Pavilion (Booth #2817)
Georgia World Congress Center
Atlanta, GA

WHEN: May 18-21, 2009
“HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a Global Pandemic” Thursday, May 21, 10-11 a.m., Room B309

WHO: Robert McNally, Ph.D., chief executive officer and president
Mark Reynolds, chief financial officer
Harriet Robinson, PhD, vice president of research and development and developer of the GeoVax vaccine

WHY: HIV Vaccine Awareness Day coincides with the opening of the conference on May 18, and Sir Elton John delivering a keynote address to include how biotechnology is influencing treatment and prevention of the diseases. GeoVax is looking forward to sharing with interested partners, investors and media its progress in clinical trials during the last six months and its strategy for the future.

FOR FURTHER INFORMATION:

At GeoVax:
Bob McNally
404.727.0971
bmcnally@geovax.com

At Financial Relations Board:
Leslie Loyet
312.640.6672
lloyet@mww.com